MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding MoonLake Immunotherapeutics changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 109 | 3 | 116 | +10 |
| Shares | 62.3M | 141.4K | 63.4M | +1.29M (+2.1%) |
| Value | $3.14B | $7.13M | $3.43B | +$301.6M (+9.6%) |
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held MoonLake Immunotherapeutics at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EcoR1 Capital, LLC | 332,522 | $18.0M | 0.72% |
| Walleye Capital LLC | 208,896 | $11.3M | 0.11% |
| Point72 Asset Management, L.P. | 98,719 | $5.35M | 0.01% |
| Dimensional Fund Advisors LP | 64,384 | $3.49M | 0.00% |
| BIT Capital GmbH | 20,748 | $1.12M | 0.10% |
| Universal- Beteiligungs- und Servicegesellschaft mbH | 20,141 | $1.09M | 0.00% |
| Caption Management, LLC | 12,371 | $669.9K | 0.03% |
| Cinctive Capital Management LP | 10,576 | $572.7K | 0.03% |
| BNP Paribas Arbitrage, SA | 7,633 | $413.3K | 0.00% |
| Hudson Bay Capital Management LP | 7,500 | $406.1K | 0.00% |
| Jefferies Financial Group Inc. | 6,250 | $338.4K | 0.00% |
| Mariner, LLC | 5,028 | $272.3K | 0.00% |
| PEAK6 LLC | 5,000 | $270.8K | 0.01% |
| KLP Kapitalforvaltning AS | 4,500 | $243.7K | 0.00% |
| Birchview Capital, LP | 4,000 | $216.6K | 0.18% |
| Parallax Volatility Advisers, L.P. | 3,208 | $173.7K | 0.00% |
| Advisors Asset Management, Inc. | 2,206 | $119.5K | 0.00% |
| Citigroup Inc | 1,212 | $65.6K | 0.00% |
| Skopos Labs, Inc. | 78 | $4.22K | 0.00% |
| Geneos Wealth Management Inc. | 14 | $758 | 0.00% |
| Amundi | 12 | $578 | 0.00% |
| National Bank of Canada | 2 | $108 | 0.00% |
| IFP Advisors, Inc | 0 | $54 | 0.00% |
Sold out (13)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Millennium Management LLC | 51,267 | $2.58M |
| Monashee Investment Management LLC | 50,000 | $2.52M |
| Altium Capital Management LP | 40,000 | $2.02M |
| Tudor Investment Corp Et Al | 31,840 | $1.61M |
| Trexquant Investment LP | 25,523 | $1.29M |
| Gsa Capital Partners LLP | 22,127 | $1.12M |
| ExodusPoint Capital Management, LP | 16,855 | $850.0K |
| J. Goldman & Co LP | 16,162 | $814.9K |
| AlphaCentric Advisors LLC | 14,000 | $705.9K |
| HRT Financial LP | 13,592 | $685.0K |
| Squarepoint Ops LLC | 6,402 | $322.8K |
| Tower Research Capital LLC (TRC) | 1,672 | $84.3K |
| Clear Street Markets LLC | 90 | $5.00K |
Not filed for Q4 2024 yet (3)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Ghost Tree Capital, LLC | 128,411 | $6.47M |
| PEAK6 Investments LLC | 13,000 | $655.5K |
| Planning Capital Management Corp | 2 | $101 |